Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 14/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21330723 | 0.89 | ROCK1 (0.47) | ROCK2ROCK1 | |
| SCHEMBL21348564 | 0.86 | ROCK2 (0.46) | ROCK2ROCK1MAOBTRPV1 | |
| SCHEMBL21348866 | 0.81 | ROCK1 (0.43) | ROCK2ROCK1 | |
| SCHEMBL21348865 | 0.77 | ROCK1 (0.46) | ROCK2ROCK1 | |
| SCHEMBL21348849 | 0.77 | ROCK1 (0.44) | ROCK2ROCK1 | |
| SCHEMBL21349130 | 0.76 | ROCK1 (0.42) | ROCK2ROCK1 | |
| SCHEMBL18056645 | 0.75 | ROCK1 (0.64) | ROCK2ROCK1 | |
| SCHEMBL18056643 | 0.70 | ROCK1 (0.58) | ROCK2ROCK1 | |
| SCHEMBL21348851 | 0.70 | ROCK1 (0.49) | ROCK2ROCK1 | |
| SCHEMBL21349133 | 0.69 | ROCK1 (0.58) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | LYCERA CORPORATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190276447-A1 | INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276447-A1 | INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | ROCK1, ROCK2, TNK2 | ROCK2 2/4885ROCK1 1/4885MAOB 4360/4885 |
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | ROCK1, ROCK2, TNK2 | ROCK2 2/4885ROCK1 1/4885MAOB 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.